Skip to main content
. 2021 Nov 1;6:374. doi: 10.1038/s41392-021-00773-3

Fig. 3.

Fig. 3

Distribution of molecular mechanisms of acquired resistance to mefatinib. Pie chart illustrating the distribution of acquired mutations identified in the cohort at the progression from mefatinib therapy